Background. Children with neurodevelopmental disabilities may be at risk of opioid-induced respiratory depression. We aimed to quantify the risks and effectiveness of morphine nurse-controlled analgesia (morphine-NCA) for postoperative pain in children with neurodevelopmental disabilities. Methods. We carried out a retrospective cohort study of 12 904 children who received postoperative i.v. morphine-NCA. Subjects were divided into a neurodevelopmental disability group and a control group. Rates of clinical satisfaction, respiratory depression, and serious adverse events were obtained, and statistical analysis, including multilevel logistic regression using Bayesian inference, was performed. Results. Of 12 904 patients, 2390 (19%) had neurodevelopmental disabilities. There were 88 instances of respiratory depression and 52 serious adverse events; there were no opioid-related deaths. The cumulative incidence of respiratory depression in the neurodevelopmental disability group was 1.09% vs 0.59% in the control group [odds ratio 1.8 (98% chance that the true odds ratio was >1)]. A significant interaction between postoperative morphine dose and neurodevelopmental disabilities was observed, with higher risk of respiratory depression with increasing dose. Satisfaction with morphine-NCA was very high overall, although children with neurodevelopmental disabilities were 1% more likely to have infusions rated as fair or poor (3.3 vs 2.1%, v
I.V. opioids are frequently used for the management of severe postoperative pain in children and are generally considered to have an acceptable safety profile. [1] [2] [3] [4] However, some patient groups may be at increased risk of opioid-induced respiratory depression (OIRD), a potentially life-threatening side-effect. 5 Neonates, especially premature neonates, and children with obstructive sleep apnoea (OSA) or renal impairment are thought to be at higher risk of OIRD; it is therefore important to identify such patients and institute appropriate monitoring if opioids are to be used with optimal safety. [2] [3] [4] [5] Children with neurodevelopmental disabilities are a large and important group, in whom the challenges of effective and safe pain management are recognized. Communication difficulties, physical and physiological impairments, pharmacokineticpharmacodynamic differences, and drug interactions add to the complexity of pain management in this group and may contribute to the suggestion that they are more susceptible to OIRD; however, few data are available. The high frequency of pain in children with neurodevelopmental disabilities and their increased likelihood of undergoing surgery 7 17 indicate a clear need for better understanding of analgesic effects in these vulnerable young people. 7 21 We aimed to quantify the risks of respiratory depression, serious adverse events, and rates of satisfaction in a group of morphine-treated postoperative children with neurodevelopmental disabilities. We hypothesized that children with neurodevelopmental disabilities would have a higher risk of both respiratory depression and serious adverse events. We have previously described the use of morphine nurse-controlled analgesia (morphine-NCA) in our institution, including some of the data presented here, although previous studies did not address the current hypothesis, and a greater number of patients are included here. 2 18 Methods
Nurse-controlled analgesia
Morphine-NCA is an i.v. morphine infusion using a locked, programmable infusion pump, with the option for additional doses ('boluses') of morphine administered on demand by nursing staff, subject to a lockout period. The NCA protocol is given in Appendix 1. 2 18 Patients receiving morphine-NCA are observed at least hourly during treatment. 24 as appropriate and as these tools became available. Sedation was measured using the University of Michigan Sedation Scale. 25 Trained nurses are permitted to deliver bolus doses after pain assessment with the aim of maintaining pain scores below 4/10 on a numerical rating scale. Simple analgesics, paracetamol, and non-steroidal antiinflammatory drugs are prescribed (unless contraindicated) for all patients and administered as appropriate. The administration of supplementary opioid analgesia is prohibited during NCA. Naloxone 4 lg kg À1 is prescribed pro re nata (as needed) for administration in the event of clinically significant respiratory depression at the discretion of clinical staff. Parents and other non-professional carers are not permitted to deliver morphine bolus doses.
Outcomes
Principal outcomes were as follows: cumulative incidence of respiratory depression; cumulative incidence of serious adverse events; and satisfaction with analgesia. 26 We deemed all instances of naloxone administration for respiratory depression as serious adverse events. Satisfaction was recorded at the end of treatment as very good, good, fair, or poor according to assessments made by trained and experienced Clinical Nurse Specialists taking into account the opinions of other clinical staff, the family, and where possible, the patient.
Patients and data
We identified all patients aged 0-18 yr who received i.v. morphine-NCA after major surgery at Great Ormond Street Children's Hospital, between 1996 and 2011. Prospectively documented data were collected at least once daily by trained and experienced Clinical Nurse Specialists and entered into a pain management patient record at the bedside, which was transcribed, when treatment was completed, to a secure electronic database. The database was maintained by trained staff and regularly reviewed; anomalous data were independently verified against original hospital records at point of entry. 2 After extraction, data were rechecked for quality and consistency using standard graphical and statistical techniques. Institutional registration and approval were obtained according to local policies (Project 1879, Great Ormond Street Hospital Clinical Audit Registration, February 2016), and data were processed in accordance with UK information governance requirements. Patients who received morphine-NCA were identified as having neurodevelopmental disabilities from the clinical patient record and divided into two groups: those with neurodevelopmental disabilities (NDG) and those without (control group, CG). Children were included in the NDG if the 'developmental delay' checkbox was completed on the patient record or the clinical diagnosis included medical conditions known to cause neurodevelopmental delay, or both, and evidence of the presence of neurodevelopmental delay had been confirmed on physical examination. Where possible, the NDG was also subdivided into groups by diagnosis (Supplementary material, Table S1 ). Data were also collected on the following known and theoretical confounders: age; weight; sex; renal impairment; OSA; operation duration (in minutes); type of surgery Editor's key points
• Children with neurodevelopmental disabilities may be at risk of opioid-induced respiratory depression, but its incidence and degree are not clear.
• The incidence of opioid-induced respiratory depression was assessed in children with and without neurodevelopmental disabilities.
• Children with neurodevelopmental disabilities were 1.8 times more likely to suffer respiratory depression.
(grouped as cardiothoracic, general, urological, head and neck, neurosurgery, orthopaedic, and plastics); administration of intraoperative opioids and dose; postoperative ward location (ward); length of NCA infusion (in hours); whether the patient was initially commenced on a background infusion and infusion rate; initial NCA bolus size; and overall postoperative morphine dose (expressed in micrograms per kilogram per hour). The day of surgery is labelled day zero (D0) and is the time between commencement of the infusion and midnight; subsequent calendar days are labelled day 1 (D1), etc., until termination of the NCA infusion.
Statistical analysis
A summary of the statistical methods is given here; see the Supplementary material (Statistical Appendix) for full details. Descriptive statistics were computed as the median (interquartile range) and n (%). Possible effect modifiers were investigated using stratification. Expectation-maximization with bootstrapping using the R package Amelia II 27 was performed to impute missing values with 10 imputed data sets. Multilevel logistic regression was used to analyse the incidence of respiratory depression and serious adverse events, allowing the intercept to vary by ward. Parameters were estimated using Bayesian inference from Markov chain Monte Carlo simulations with Gibbs sampling (see Supplementary material, Statistical Appendix for details on handling of missing data and Bayesian set-up). Model fit was assessed by examining the deviance information criterion (DIC) of each model: lower values of the DIC represent better fit; a change of 5 units indicates some substantial improvement, and change of 10 units definite improvement. As any increase in the risk of respiratory depression or serious adverse events was considered clinically important, we calculated the probability that the true odds ratio (OR) for neurodevelopmental disability (ND) was >1 in each model by computing the area under the curve of the posterior distribution, which represented an OR >1. 
Results

Patient characteristics and morphine dose
Twelve thousand, nine hundred and four patients were included; the prevalence of neurodevelopmental disabilities was 19% (n¼2390). There were missing data on the following variables: duration of operation (n¼1037, 8.0%), intraoperative opioid administration (n¼958, 7.4%), infusion background, background rate, and bolus size (n¼44, 0.3% on all three), and overall postoperative morphine dose (n¼148, 1.1%). The patient characteristics, duration of operation, and duration of morphine-NCA are shown in Table 1 (surgical categories broken down by group are given in the Supplementary material, Table S2 ). Patients in the NDG were older and heavier (older patients in the control group are usually commenced on patient-controlled analgesia), were more likely to have OSA, and had longer durations of operation and postoperative morphine-NCA infusion (though these were not significantly different from the CG in all subgroups of ND).
The median postoperative morphine dose in the NDG was 16.31 lg kg À1 h À1 on D0, compared with 15.02 lg kg À1 h À1 in the CG ( Table 2 ). As expected, the morphine dose declined with each consecutive postoperative day in all groups. The values for all opioid doses are given in the Supplementary material (Tables  S3-S6 ) and were included in the overall analysis.
Respiratory depression
There were 88 instances of respiratory depression; 26 were in the NDG (cumulative incidence 1.09%) and 62 were in the CG (cumulative incidence 0.59%; Table 3 ). Further comparison by NDG diagnostic subgroup suggested that patients with cerebral palsy, Down's syndrome, or encephalopathy appear to be most at risk of respiratory depression (1.68, 1.84, and 2.53 vs 0.59%; Table 3 ). About half of the incidents of respiratory depression occurred on D0, and 92% occurred within the first 48 h (Supplementary material, Table S7); the pattern was similar in both the NDG and CG. The distribution of respiratory depression among the covariates and stratified by NDG/CG is given in the Supplementary material (Tables S8 and S9 ). Figure 1A shows the posterior distribution of the effect of neurodevelopmental disability on the odds of respiratory depression in an unadjusted model. It shows that the odds of respiratory depression were 65% (OR 1.65, 95% CrI 1.03-2.63) higher in children in the NDG compared with those in the CG. There was a 98% chance that the true OR was >1.
Further models were constructed, and the results did not change appreciably; details of these models can be found in the Supplementary material (Table S10) , and the respective posterior distributions for the effect of neurodevelopmental disabilities can also be found in the Supplementary material (Fig. S1 ). In summary, in model 3, the effect of ND was augmented to OR 1.79 (95% CrI 1.05-3.04) after adjusting for age (age being a very important predictor in all models, with older patients having a much lower risk of respiratory depression than neonates). Gender, presence of renal impairment, and OSA were not significant. Surgical category was entered in model 4, and this attenuated the effect size slightly, but surgery was not significant, did not improve model fit, and so was discarded. In model 5, the administration of intraoperative opioids, commencement on a background infusion, NCA bolus size, and overall postoperative morphine dose on D0 were all not significant predictors of respiratory depression. Likewise, in model 6, there was no evidence of a time effect, with year of surgery being insignificant.
A morphine-neurodevelopmental disabilities interaction term was entered and was significant (model 7). This is illustrated in Fig. 2A , which indicates that the risk of respiratory depression in patients in the NDG increased with increasing postoperative doses of morphine within a therapeutic range, whereas this did not occur in the CG. This model had the best fit of all seven (lowest DIC).
The ward intercept SD in the model with no predictors (model 1) showed a degree of variability in the odds of respiratory depression by ward, which ranged from 0.001 to 0.023. About 62% of this variability was attributable to differences in ages and surgical categories of the patients seen on each ward; the remaining variability was not accounted for by the other measured variables.
Serious adverse events
There were 52 serious adverse events. Forty-nine serious adverse events were respiratory depression treated with naloxone; three were judged not opioid related. Fourteen serious adverse events (0.59%) occurred in the NDG vs 38 (0.36%) in the CG (absolute risk difference 0.23%). Half of the serious adverse events occurred on D0 and 92% within the first 48 h in both the NDG and CG (Supplementary material, Table S7 ). The posterior distribution for the OR of neurodevelopmental disabilities in the unadjusted serious adverse event model is given in Fig. 1B , which shows that those with neurodevelopmental disabilities were 1.42 times more likely to experience a serious adverse event, although as the 95% CrI crossed 1 (0.77-2.63) this finding was interpreted as non-significant. Results did not change appreciably in further models (Supplementary ma terial, Table S11 and Fig. S1 ). Age was an important risk factor (as with respiratory depression), and none of gender, renal impairment, surgical category, intraoperative and postoperative opioid administration, or year was significant (models 3-6).
There was a shallow interaction between postoperative morphine and neurodevelopmental disabilities (model 7), as shown in Fig. 2B ; this model had the best fit. The degree of variability in the risk of serious adverse events attributable to ward was similar to that for respiratory depression.
Satisfaction
Overall, satisfaction was very good or good in 12 320 (98%) patients and fair or poor in 288 (2%). Morphine-NCA in the NDG was 1.2% more likely to be rated fair or poor than in the 
Discussion
This is the first large-scale study specifically attempting to quantify, examine, and gain a better understanding of the risks of OIRD in children with neurodevelopmental disabilities. We compared 2390 children with the disabilities with 10 514 without disabilities, who were receiving morphine after major surgery, and found that the presence of the disabilities, after correcting for confounders, was associated with greater risk of experiencing respiratory depression; a significant interaction between neurodevelopmental disabilities and postoperative morphine dose was also found. Although respiratory depression was more prevalent in the NDG, in the present study there appeared to be little or no difference in the risk of experiencing serious adverse events, which is reassuring. Neurodevelopmental disabilities are a group of congenital or acquired long-term conditions that are attributed to impairment of the brain, neuromuscular system, or both, and create functional limitations. Although easily identified clinically, they comprise a heterogeneous group where a specific diagnosis is not always ascribed. Such conditions may or may not be progressive, occur alone or in combination, and in a broad range of severity and complexity. Their impact may include difficulties with movement, cognition, hearing and vision, communication, emotion, and behaviour. 28 Children with neurodevelopmental disabilities represent a significant proportion of children undergoing surgery and therefore postoperative pain, and in fact, have been considered to be at increased risk of experiencing all types of pain. 17 29-32 Despite this, few data are available to guide management, and in fact, they are often specifically excluded from research studies and have been estimated to be represented in only 0.03% of the pain literature. 33 34 Respiratory depression is often considered to be a predictable side-effect of opioid analgesia, but it is the possible progression to cardiorespiratory collapse that could lead to serious permanent harm, or even death, that has been identified as the greatest safety concern for clinicians. 5 35 Fortunately, awareness of this potential, the recognition of patient groups 'at risk', and provision of appropriate monitoring has probably contributed to the low reported rates of serious harm, although there is concern that such low rates, the lack of a generally accepted definition of respiratory depression, methodological problems in undertaking multisite population studies, under-reporting of individual instances, and the small size of many studies in children may underestimate the true incidence of both respiratory depression and serious complications. 35 In the present singlecentre study, we found the overall rates of respiratory depression to be reassuringly low (0.59-1.09%) but nevertheless slightly above the range of estimates from previous multisite studies. 36 In strong agreement with previous studies, patient age was the most consistent and important predictor of respiratory depression in all patients in the present study. The finding here that the generally accepted risk factors, OSA and renal impairment, did not predict respiratory depression may imply that such risks can be attenuated successfully; a concept further supported by the low rate of progression to serious adverse events that was observed in all groups.
Aside from the increased risk of respiratory depression, we also observed an increased 'sensitivity' to morphine in the NDG; that is, patients with neurodevelopmental disabilities appeared to be more likely to experience respiratory depression with increasing morphine dose. The reasons for this are unclear, but children with the disabilities may have impaired respiratory drive, cardiorespiratory deficits, neuromuscular and postural abnormalities, and gastro-oesophageal reflux, and are more likely to be treated with anti-epileptics, muscle relaxants, sedatives, and other medicines that were not controlled for in this study. 7 11 Whilst providing some data on the incidence and risks of OIRD in patients with neurodevelopmental disabilities, previous studies have been difficult to interpret because of differences in study design, patient population, opioid drug, route, dose and dosing frequency, monitoring practices, reporting criteria, and the lack of control groups. 3 9 15 16 37 38 A small retrospective cohort study by Long and colleagues 9 found no differences in the risk of 'clinically significant oxygen desaturation' (peripheral oxygen saturation 94%) between a group of children with (n¼71) and without cerebral palsy (n¼77) in the postanaesthesia care unit, whereas a case-control study by Chidambaran and colleagues, 16 analysing 38 instances of naloxone administration to inpatients in a tertiary children's hospital, reported risk factors of <1 yr, prematurity, OSA, obesity, underweight, and developmental delay.
How profound and what types of neurodevelopmental disabilities might increase the predisposition to respiratory depression is not known. In the present study, children with cerebral palsy (non-progressive neurodevelopmental disabilities attributable to perinatal causes), Down's syndrome, and encephalopathy appear to be at relatively greatest risk of developing both respiratory depression and serious adverse events. Adverse perinatal events are known to influence subsequent development of respiratory control; therefore, further study of the underlying mechanisms might lead to important clues regarding potential causation. 39 However, given that firm conclusions regarding relative risks in subgroups were difficult in the present study because numbers were too low to perform multivariable analysis, further clinical study would also be required.
Strengths and limitations
Although our study was conducted retrospectively using routine clinical data, those data were collected prospectively according to a mandatory, rigorous protocol and therefore not subject to recall bias. It is possible that the overall prevalence of neurodevelopmental disabilities might have been under-reported, leading to bias to the null, but as the estimated lifetime prevalence of neurological disorders in the UK is 6%, the higher prevalence (19%) found here, along with the data collection protocol, should have ensured that any effect of under-reporting of neurodevelopmental disabilities was successfully minimized. 40 Although serious adverse events or instances of respiratory depression could also have been unreported, we feel that this is unlikely because they would have been recorded and investigated at the time they occurred. There were a number of potentially relevant variables for which we were unable to adjust; for example, the incidence of respiratory depression or serious adverse events might also be driven by provider-level characteristics, such as the quality and volume of nursing care. Although it was not possible to examine the effect of individual nursing teams (e.g. their experience and training) in this analysis, we did model the contextual effect of individual wards.
Conclusions and clinical implications
Morphine-NCA is an acceptable method of postoperative analgesia in children with and without neurodevelopmental disabilities. Postoperative children with ND appear to be at higher risk of developing OIRD with morphine-NCA than children without ND, although the risk remains low within the parameters of this study. Although children with ND did not experience significantly higher rates of serious adverse events, they were nevertheless 1% more likely to have a less satisfactory rating of morphine-NCA.
